MICHEL MAHARBIZ, P.h.D
FOUNDER and CEO
Michel’s research focuses on the miniaturization of technology focused on building synthetic interfaces to cells and organisms. He is a professor of EECS at UC Berkeley. He is known as one of the inventors of “neural dust”, an ultrasonic interface for vanishingly small implants in the body. Michel received his B.S. from Cornell University and his Ph.D. from the University of California, Berkeley.
JOSE CARMENA, P.h.D
FOUNDER and CSO
Jose’s research focuses on brain-machine interfaces, leveraging neuroplasticity, machine learning, and neurotechnology to ask how the brain learns and controls movement, and to develop smart prosthetics and neurotherapies. He is co-inventor of the “neural dust” technology platform. Jose is a professor of EECS and Neuroscience at UC Berkeley, and received his B.S. and M.S. from the Universidad Politecnica de Valencia and Universidad de Valencia in Spain, and his Ph.D. from the University of Edinburgh in Scotland.
Nick has held positions at Baxter as global head of business development, Takeda as head of International business development, and TAP as VP of business development. Prior to TAP, Nick spent 17 years at Abbott in a variety of roles of increasing responsibility. Nick holds an MBA from the Northwestern University J.L. Kellogg School of Management.
LEAD SYSTEMS ENGINEER
Josh’s interdisciplinary expertise across the fields of electrical engineering, computer science, and bioengineering includes ASICs, sensors, DSP, and implantable technology. Josh graduated with his B.S in electrical engineering from UC Santa Barbara in 2014 and received his M.S. in electrical engineering and computer science from UC Berkeley in 2017. He became involved in the dust technology as a researcher at UC Berkeley, where he designed a wearable ultrasound device for neural interfacing.
RYAN NEELY, Ph.D.
DIRECTOR OF SYSTEMS AND DESIGN
Ryan approaches neural engineering with an extensive background in molecular, cellular, and systems neuroscience. His career in research began in 2008 and has evolved from the study of individual synapses to single neurons and finally to large-scale neural circuits that support learning in brain-machine interfaces. He has held research positions at the University of Michigan’s Molecular and Behavioral Neuroscience Institute and the Harvard Center for Brain Science. Ryan received his B.A. in neurobiology from Harvard University and his Ph.D. from the University of California, Berkeley, where he was a key contributor to the development and validation of neural dust technology.
Feeling frustrated by traditional “silo” trading and risk management technologies as a derivatives trader, Coleman launched OpenLink in 1992 to challenge market conventions with a unique and open technology platform. As the initial business architect, he laid this cross-market risk architecture – which is still unique today – for a robust environment that seamlessly supports front- through back-office requirements for financial and energy/commodity markets. The company was chosen as the inaugural winner of Risk Management Innovator of the Year by Platts in 2007.
After retiring from the CEO and Chairman positions at OpenLink, Coleman has been devoting significant amounts of his energy and resources (through the Coleman Fung Foundation) to a number of worthy causes and projects, including creating the Coleman Fung Institute for Engineering Leadership at the University of California, Berkeley. In addition, Coleman has co-founded Blue Goji with his fellow Berkeley friends, perusing his new interests in active gaming/active VR, gamification of health, and health risk management and prevention.
Coleman holds a master’s degree in Industrial Engineering from Stanford University and a bachelor’s degree in Industrial Engineering/Operations Research from the University of California, Berkeley, and he also served in the US Army.
Richard Passov has more than 25 years of leadership experience across technology and life science companies. He helped capitalize Sun Microsystems through its hyper-growth phase, leaving to join Intel where he became one of the first employees in Intel’s Venture Capital group. He helped steer Pfizer through $250 billion of acquisitions, strategic reviews of R&D productivity, the outsourcing of clinical trails and led the divestiture of Zoetis and it’s successful IPO. He’s on the board of OffAssignment, the Finance Committee of OneAcreFund, and the Advisory Board for IEOR at UC Berkeley. He received a B.A. and M.B.A from the University of California, Los Angeles along with an M.S., Operations Research from the University of California, Berkeley.
TIM OPLER, Ph.D.
Tim has 24 years experience leading strategic and financing transactions across multiple sectors. For nearly 20 years, he has focused exclusively on life sciences advisory; he has completed more than 150 financing, licensing, and M&A transactions across the industry with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron’s $5.1 billion sale to Novartis, and managing Genentech’s inaugural $2 billion bond issue. Before co-founding Torreya, Tim was Vice President of Strategy at FibroGen, where he helped raise $117 million for the company and negotiated licensing deals. Previously, Tim was a Managing Director in Healthcare Investment Banking at Credit Suisse First Boston and held senior roles at W.R. Hambrecht, Deutsche Bank, and Merrill Lynch. Prior to his career in investment banking, Tim was a professor in the finance department at Ohio State University. He earned a B.S. in economics and philosophy from Florida State University, and a Ph.D. in economics from UCLA.